{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:22:43Z","timestamp":1769595763174,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["16\/10\/02"],"award-info":[{"award-number":["16\/10\/02"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40273-019-00779-4","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T02:03:28Z","timestamp":1552961008000},"page":"1081-1091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-0699","authenticated-orcid":false,"given":"Edward","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ros","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Peron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina Charlotte","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Eastwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"779_CR1","unstructured":"National Institute for Health and Care Excellence. Guide to the single technology appraisal process. 2009. \n                    https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/Guide-to-the-single-technology-appraisal-process.pdf\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR2","unstructured":"Wade, R., et al. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/ta541\/documents\/committee-papers-2\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR3","unstructured":"National Institute of Health and Care Excellence. Guide to the methods of technology appraisal. 2013. \n                    https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR4","unstructured":"National Institute for Health and Care Excellence. Inotuzumab ozogamicin for treating relapsed or refractory acute lymphoblastic leukaemia [ID893]. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10091\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR5","unstructured":"Cancer Research UK. Acute lymphoblastic leukaemia (ALL) incidence statistics. 2014. \n                    http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-all\/incidence#heading-Zero\n                    \n                  . Accessed Jan 2018."},{"issue":"9881","key":"779_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943\u201355.","journal-title":"Lancet."},{"key":"779_CR7","unstructured":"American Cancer Society. What are the key statistics about acute lymphocytic leukemia? 2017. \n                    https:\/\/www.cancer.org\/cancer\/acute-lymphocytic-leukemia\/about\/key-statistics.html#references\n                    \n                   Accessed 5 Jan 2017."},{"issue":"6","key":"779_CR8","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.","journal-title":"Blood Cancer J"},{"issue":"12","key":"779_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N Gokbuget","year":"2016","unstructured":"Gokbuget N, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333.","journal-title":"Haematologica"},{"key":"779_CR10","unstructured":"National Institute for Health and Care Excellence. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/ta450\/history\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR11","unstructured":"European Medicines Agency, Besponsa. EPAR\u2014Public assessment report. EMA\/269417\/2017. 2017."},{"key":"779_CR12","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Final scope. 2016. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/final-scope\n                    \n                  . Accessed 8 Jan 2018."},{"issue":"8","key":"779_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"779_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"11","key":"779_CR15","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186\u201391.","journal-title":"Cancer"},{"issue":"4","key":"779_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol A, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589\u201396.","journal-title":"Haematologica"},{"issue":"7","key":"779_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216\u201330.","journal-title":"Cancer"},{"issue":"6","key":"779_CR18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.bbmt.2016.03.015","volume":"22","author":"S Kurosawa","year":"2016","unstructured":"Kurosawa S, et al. Decision analysis of postremission therapy in cytogenetically intermediate-risk acute myeloid leukemia: the impact of FLT3 internal tandem duplication, nucleophosmin, and CCAAT\/enhancer binding protein alpha. Biol Blood Marrow Transpl. 2016;22(6):1125\u201332.","journal-title":"Biol Blood Marrow Transpl"},{"key":"779_CR19","doi-asserted-by":"crossref","unstructured":"Boluda, B., et al., Time and cost of hospitalisation for salvage therapy among adults with Philadelphia (Ph)-negative B-cell relapsed\/refractory (R\/R) acute lymphoblastic leukaemia (ALL) in Spain. In: ISPOR 19th annual European congress, Vienna, Austria; 2016.","DOI":"10.1016\/j.jval.2016.09.2171"},{"issue":"11","key":"779_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1080\/13696998.2016.1192549","volume":"19","author":"H Dombret","year":"2016","unstructured":"Dombret H, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. J Med Econ. 2016;19(11):1034\u20139.","journal-title":"J Med Econ"},{"issue":"6","key":"779_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","volume":"28","author":"PJ Martin","year":"2010","unstructured":"Martin PJ, et al. Life expectancy in patients surviving more than 5\u00a0years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011\u20136.","journal-title":"J Clin Oncol"},{"key":"779_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Appraisal consultation document Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/appraisal-consultation-document\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR23","unstructured":"National Institute for Health and Care Excellence. Committee Papers - Final appraisal determination Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID893]. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/committee-papers\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR24","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/final-appraisal-determination-document\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR25","unstructured":"National Institute for Health and Care Excellence. Pfizer Ltd: Appeal letter. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/appeal-letter\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR26","unstructured":"National Institute for Health and Care Excellence. Appeal hearing\u2014advice on inotuzumab ozogamicin for treating relapsed refractory B-cell acute lymphoblastic leukaemia: Decision of the panel. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/appeal-decision-2\n                    \n                  . Accessed 8 Jan 2018."},{"key":"779_CR27","unstructured":"National Institute for Health and Care Excellence. Appraisal consultation 2: committee papers\u2014inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID893]. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/committee-papers-3\n                    \n                  . Accessed 3 Sept 2018."},{"key":"779_CR28","unstructured":"National Institute for Health and Care Excellence. Appraisal consultation 2: appraisal consultation document\u2014Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/appraisal-consultation-document-2\n                    \n                  . Accessed 3 Sept 2018."},{"key":"779_CR29","unstructured":"National Institute for Health and Care Excellence. Final appraisal document: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10091\/documents\/final-appraisal-determination-document-2\n                    \n                  . Accessed 3 Sept 2018."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00779-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:10:39Z","timestamp":1584490239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00779-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00779-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"19 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project number 16\/10\/02). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer and Susan Griffin have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}